Stockscreener 앱 받기
3.60
6.49%
-0.25
시간 외 거래:
3.61
0.010
+0.28%
전일 마감가:
$3.85
열려 있는:
$3.82
하루 거래량:
1.65M
Relative Volume:
0.97
시가총액:
$386.70M
수익:
$42.51M
순이익/손실:
$-116.49M
주가수익비율:
-2.9752
EPS:
-1.21
순현금흐름:
$-120.82M
1주 성능:
+6.51%
1개월 성능:
-51.74%
6개월 성능:
-52.13%
1년 성능:
-52.63%
1일 변동 폭
$3.54
$3.84
1주일 범위
$3.255
$4.1391
52주 변동 폭
$2.70
$13.01
Tango Therapeutics Inc Stock (TNGX) Company Profile
명칭
Tango Therapeutics Inc
전화
(857) 320-4900
주소
201 BROOKLINE AVENUE, BOSTON
TNGX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| TNGX | 3.60 | 386.70M | 42.51M | -116.49M | -120.82M | -1.21 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Tango Therapeutics Inc Stock (TNGX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-12-08 | 개시 | B. Riley Securities | Buy |
| 2022-10-20 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2021-09-20 | 개시 | SVB Leerink | Outperform |
Tango Therapeutics Inc 주식(TNGX)의 최신 뉴스
Trv Gp Iv LLC Has $129.82 Million Position in Tango Therapeutics, Inc. (NASDAQ:TNGX) - MarketBeat
Tango Therapeutics, Inc. (NASDAQ:TNGX) Receives Average Rating of "Buy" from Analysts - MarketBeat
B. Riley Increases Earnings Estimates for Tango Therapeutics - Defense World
B. Riley Forecasts Higher Earnings for Tango Therapeutics - MarketBeat
B. Riley Cuts Tango Therapeutics (NASDAQ:TNGX) Price Target to $8.00 - Defense World
Tango Therapeutics' SWOT analysis: stock outlook amid PRMT5 inhibitor progress - Investing.com
Tango Therapeutics (NASDAQ:TNGX) Earns “Buy” Rating from HC Wainwright - Defense World
The Analyst Landscape: 5 Takes On Tango Therapeutics - Benzinga
B. Riley Has Lowered Expectations for Tango Therapeutics (NASDAQ:TNGX) Stock Price - MarketBeat
FY2024 Earnings Forecast for TNGX Issued By Leerink Partnrs - Defense World
Leerink Partnrs Brokers Increase Earnings Estimates for TNGX - MarketBeat
EcoR1 Capital sells $8.4 million in Tango Therapeutics stock - Investing.com India
EcoR1 Capital sells $8.4 million in Tango Therapeutics stock By Investing.com - Investing.com Australia
Tango Therapeutics' (TNGX) Buy Rating Reiterated at HC Wainwright - MarketBeat
Wedbush Has Pessimistic Outlook of TNGX FY2024 Earnings - Defense World
EcoR1 Capital, LLC Adjusts Stake in Tango Therapeutics Inc - GuruFocus.com
Wedbush Forecasts Reduced Earnings for Tango Therapeutics - MarketBeat
Tango Therapeutics Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Tango Therapeutics sees $9.67m stock sale by Boxer Capital - Investing.com India
Tango Therapeutics (NASDAQ:TNGX) Price Target Lowered to $8.00 at Guggenheim - MarketBeat
Tango Therapeutics Advances Cancer Treatment Pipeline - TipRanks
Two to Tango: Brain cancer drugs go further into development - BioWorld Online
Tango stock plunges 28% amid pipeline updates, Q3 earnings report (NASDAQ:TNGX) - Seeking Alpha
U.S. Stock market: Sunnova energy(-42.35%0, Zoomcar(-38.48%), Tango therapeutics(-27.22%) among stock losers during early trading - Business Upturn
Tango Shares Plunge After 3Q Loss, Product Plans - MarketWatch
Tango Therapeutics advances cancer drug into full development By Investing.com - Investing.com Canada
Tango Therapeutics, Inc. (TNGX) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
Tango Therapeutics Reports Positive TNG462 Clinical Data and Provides Update on PRMT5 Development Program - BioSpace
Tango Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Tango Therapeutics advances cancer drug into full development - Investing.com
Tango Therapeutics Reports 43% Response Rate in Cancer Trial, Secures $293M Cash Runway | TNGX Stock News - StockTitan
Tango's TNG462 Cancer Drug Shows Promise; New Brain-Penetrant Treatment Unveiled | TNGX Stock News - StockTitan
Tango Therapeutics (NASDAQ:TNGX) Hits New 52-Week LowTime to Sell? - MarketBeat
Tango Therapeutics, Inc.'s (NASDAQ:TNGX) 26% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio - Simply Wall St
Tango Therapeutics (NASDAQ:TNGX) Stock Rating Reaffirmed by HC Wainwright - Defense World
Tango Therapeutics (NASDAQ:TNGX) Sets New 12-Month Low After Insider Selling - Defense World
Tango Therapeutics (NASDAQ:TNGX) Reaches New 12-Month Low Following Insider Selling - MarketBeat
Tango Therapeutics (NASDAQ:TNGX) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance
Tango Therapeutics target held at $13 by H.C. Wainwright - Investing.com
Tango Therapeutics (NASDAQ:TNGX) Sees Strong Trading VolumeHere's Why - MarketBeat
Short Interest in Tango Therapeutics, Inc. (NASDAQ:TNGX) Decreases By 17.7% - MarketBeat
Tango Therapeutics, Inc. (NASDAQ:TNGX) Insider Sells $4,348,710.00 in Stock - MarketBeat
Tango Therapeutics (NASDAQ:TNGX) Receives Buy Rating from HC Wainwright - MarketBeat
Tango Therapeutics sees $4.3 million stock sale by Boxer Capital - Investing.com Australia
Tango Therapeutics (NASDAQ:TNGX) Stock Price Up 8.7%Time to Buy? - MarketBeat
Tango Therapeutics sees $6.1 million stock sale by Boxer Capital - Investing.com Australia
(TNGX) Proactive Strategies - Stock Traders Daily
Tango Therapeutics, Inc. (NASDAQ:TNGX) Insider Boxer Capital Management, Llc Sells 625,000 Shares - MarketBeat
Tango Therapeutics (NASDAQ:TNGX) Hits New 1-Year LowHere's What Happened - MarketBeat
Tango Therapeutics Inc (TNGX) Stock Price & Chart | Trade Now - Capital.com
Ares Management Co. (NYSE:ARES) Shares Acquired by Vontobel Holding Ltd. - Defense World
Tango Therapeutics Inc (TNGX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.66%
1.11%
자본화:
|
볼륨(24시간):